
Labcorp ownership: holders and insider trading
$370.48−0.49%Close 13 Nov 2026 · Market value $30.04B
As filed, its directors and officers own 0.8% of the shares (proxy statement, 26 Mar 2026); 1,043 institutional managers reported holding 97.9% at 30 Jun 2026. Over the last twelve months, insiders sold $10.41M of shares on the open market, $6.67M of it under 10b5-1 plans set in advance, and bought none.
From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.
Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|
| Vanguard | Institution | 9.9M | 12.18%* | Form 13F | 30 Jun 2026 |
|---|
| BLACKROCK, INC. | Holder | 6.6M | 8.10%* | Form 13F | 30 Jun 2026 |
|---|
| Vanguard Capital Management | Holder | 6.2M | 7.52% | Schedule 13G | 31 Mar 2026 |
|---|
| Victory Capital Management Inc | Institution | 4.8M | 5.96%* | Form 13F | 30 Jun 2026 |
|---|
| State Street | Institution | 3.9M | 4.81%* | Form 13F | 30 Jun 2026 |
|---|
| Boston Partners | Institution | 3.1M | 3.76%* | Form 13F | 30 Jun 2026 |
|---|
| Allspring Global Investments Holdings, LLC | Institution | 2.2M | 2.75%* | Form 13F | 30 Jun 2026 |
|---|
| Geode Capital Management | Institution | 2.2M | 2.70%* | Form 13F | 30 Jun 2026 |
|---|
| Select Equity Group, L.P. | Institution | 2.0M | 2.44%* | Form 13F | 30 Jun 2026 |
|---|
| Fidelity (FMR) | Institution | 1.9M | 2.35%* | Form 13F | 30 Jun 2026 |
|---|
| Morgan Stanley | Institution | 1.6M | 1.98%* | Form 13F | 30 Jun 2026 |
|---|
| UBS | Institution | 1.4M | 1.73%* | Form 13F | 30 Jun 2026 |
|---|
| Dimensional Fund Advisors | Institution | 1.4M | 1.68%* | Form 13F | 30 Jun 2026 |
|---|
| JPMorgan Chase | Institution | 1.3M | 1.56%* | Form 13F | 30 Jun 2026 |
|---|
| Invesco | Institution | 1.2M | 1.52%* | Form 13F | 30 Jun 2026 |
|---|
| Nordea Investment Management AB | Institution | 916K | 1.13%* | Form 13F | 30 Jun 2026 |
|---|
| Northern Trust | Institution | 883K | 1.09%* | Form 13F | 30 Jun 2026 |
|---|
| Wellington Management | Institution | 856K | 1.05%* | Form 13F | 30 Jun 2026 |
|---|
| American Century Companies Inc | Institution | 845K | 1.04%* | Form 13F | 30 Jun 2026 |
|---|
| Bank of America | Institution | 812K | 1.00%* | Form 13F | 30 Jun 2026 |
|---|
Insider transactions latest 25
| Insider | Date | Transaction | Shares | Price | Value |
|---|
| ANDERSON KERRII B · Director | 17 Aug 2026 | Open-market sale (10b5-1 plan) | −3.0K | $318.02 | $954.1K |
|---|
| Schechter Adam H · President & CEO · Director | 11 Aug 2026 | Open-market sale (10b5-1 plan) | −4.7K | $320.37 | $1.50M |
|---|
| Summy Amy B. · EVP, Chief Marketing Officer | 4 Aug 2026 | Open-market sale | −924 | $306.74 | $283.4K |
|---|
| Wilkinson Peter J · SVP, Chief Accounting Officer | 3 Aug 2026 | Open-market sale | −1.3K | $309.23 | $413.7K |
|---|
| Wilkinson Peter J · SVP, Chief Accounting Officer | 3 Aug 2026 | Option exercise | +1.3K | $209.25 | $280.0K |
|---|
| Wilkinson Peter J · SVP, Chief Accounting Officer | 3 Aug 2026 | Open-market sale | −82 | $309.22 | $25.36K |
|---|
| Kyle Kathryn W · EVP, Chief Legal Officer | 2 Jul 2026 | Open-market sale (10b5-1 plan) | −92 | $286.19 | $26.33K |
|---|
| Vaughn Bryan T · EVP and President, Diagnostics | 2 Jul 2026 | Open-market sale (10b5-1 plan) | −234 | $286.19 | $66.97K |
|---|
| Kyle Kathryn W · EVP, Chief Legal Officer | 1 Jul 2026 | Option exercise | +256 | — | — |
|---|
| Kyle Kathryn W · EVP, Chief Legal Officer | 1 Jul 2026 | Shares withheld for tax | −73 | $283.88 | $20.72K |
|---|
| Vaughn Bryan T · EVP and President, Diagnostics | 1 Jul 2026 | Shares withheld for tax | −93 | $283.88 | $26.40K |
|---|
| Vaughn Bryan T · EVP and President, Diagnostics | 1 Jul 2026 | Option exercise | +327 | — | — |
|---|
| Kyle Kathryn W · EVP, Chief Legal Officer | 8 Jun 2026 | Open-market sale (10b5-1 plan) | −762 | $263.89 | $201.1K |
|---|
| Schechter Adam H · President & CEO · Director | 11 May 2026 | Open-market sale (10b5-1 plan) | −5.9K | $254.50 | $1.50M |
|---|
| Wilkinson Peter J · SVP, Chief Accounting Officer | 27 Mar 2026 | Open-market sale (10b5-1 plan) | −1.6K | $267.05 | $436.1K |
|---|
| Meltzer Jonathan C · EVP, Operations | 27 Mar 2026 | Open-market sale (10b5-1 plan) | −839 | $267.05 | $224.1K |
|---|
| Schechter Adam H · President & CEO · Director | 26 Mar 2026 | Shares withheld for tax | −26.1K | $268.38 | $7.01M |
|---|
| Schechter Adam H · President & CEO · Director | 26 Mar 2026 | Grant or award | +58.5K | — | — |
|---|
| GRAHAM ANITA Z · EVP, CHRO | 26 Mar 2026 | Grant or award | +6.6K | — | — |
|---|
| GRAHAM ANITA Z · EVP, CHRO | 26 Mar 2026 | Shares withheld for tax | −2.9K | $268.38 | $772.7K |
|---|
| Schroeder Mark S · EVP, Pres Diagnostics & COO | 26 Mar 2026 | Shares withheld for tax | −1.5K | $268.38 | $394.0K |
|---|
| Schroeder Mark S · EVP, Pres Diagnostics & COO | 26 Mar 2026 | Grant or award | +3.0K | — | — |
|---|
| Schroeder Mark S · EVP, Pres Diagnostics & COO | 26 Mar 2026 | Shares withheld for tax | −4.6K | $268.38 | $1.23M |
|---|
| Schroeder Mark S · EVP, Pres Diagnostics & COO | 26 Mar 2026 | Grant or award | +9.3K | — | — |
|---|
| Caveney Brian J · EVP, Pres of ED, CMO & CSO | 26 Mar 2026 | Grant or award | +9.3K | — | — |
|---|
Form 4 filings since 16 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.
LH in the terminal
Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.